|
gptkb:GSK
|
vector vaccines
|
|
gptkb:GSK
|
nanoparticle vaccines
|
|
gptkb:Cure_Vac's_m_RNA_vaccine
|
based on m RNA technology
|
|
gptkb:GSK
|
based on recombinant DNA
|
|
gptkb:Biontech
|
RNA-based therapeutics
|
|
gptkb:GSK
|
adjuvants
|
|
gptkb:Can_Sino_Biologics
|
recombinant technology
|
|
gptkb:Biontech
|
platform technology
|
|
gptkb:Astra_Zeneca
|
gptkb:virus
|
|
gptkb:Coalition_for_Epidemic_Preparedness_Innovations_(CEPI)
|
innovative solutions
|
|
gptkb:Biontech
|
next-generation vaccines
|
|
gptkb:Biontech
|
lipid nanoparticles
|
|
gptkb:Coalition_for_Epidemic_Preparedness_Innovations_(CEPI)
|
platform technologies
|
|
gptkb:Novavax
|
adjuvanted protein subunit
|
|
gptkb:Pfizer
|
lipid nanoparticles
|
|
gptkb:Cure_Vac's_COVID-19_vaccine_trial
|
innovative
|
|
gptkb:Novavax
|
recombinant nanoparticle technology
|